if the data is good, they will feel sky high regardless of where it is announced -- be it at the shareholder meeting or in a conference call. if the data is bad, the last thing they want to do is be sued for fraud by hiding the data in order to rig the voting. the data will be released asap when it becomes available and the annual meeting will not have any influence on it less the company want to open themselves to being sued for withholding data to rig the voting.
the filing said "by mid july" not mid july; so it could come in either early july or mid july. seeing that they were already wrong with their june projection, it would make sense for them to be more conservative in their new estimate. also, most analysis for cancer trials of this size usually takes anywhere from 2.5 to 3 months after trigger. if anything, the timeline probably just got squeezed out of the june projection by a few days. so, my money is on early july readout. so, july option should be in play.